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Abstract
Objective: Estrogen replacement therapy remains current as a therapeutic approach to 
treat menopausal symptoms and may significantly affect hormone-producing cells in the 
female pituitaries. The aim of this study was to examine the histological parameters of 
pituitary mammotrophs and prolactin secretion after chronic estradiol treatment in ovariec-
tomized adult female rats, reflecting premature menopause. 
Materials and Methods: In this experimental study, adult female Wistar rats were di-
vided into non-ovariectomized (C), ovariectomized (OVX) and estradiol-treated ova-
riectomized (OVX+E) groups. Estradiol dipropionate [0.625 mg/kg body mass per 
day] was administered for four weeks, while the C and OVX groups received vehicle 
alone. Mammotrophs were identified by the peroxidase-antiperoxidase (PAP) immu-
nohistochemical procedure, while prolactin concentrations were measured by the 
non-isotopic two-step assay (Delfia) method. Comparison of the differences between 
groups was performed using one-way analysis of variance (ANOVA) and Tukay (hon-
est significant difference) HSD test.      
Results: Ovariectomy caused significant (P<0.05) decreases in mammotroph optical 
density (OD), volume density (VV) and number per mm
2 by 29, 27 and 34%, respec-
tively, in comparison with the C females. In the OVX+E group, significant (P<0.05) 
increases in OD, cell volume, VV and number of mammotrophs per mm
2 by 181, 15%, 
5.8-fold and 5.2-fold, respectively, were observed when compared to OVX animals. 
The serum prolactin concentration in OVX females was significantly (P<0.05) de-
creased by 14% in comparison to the C group, while in OVX+E females, prolactin 
levels were significantly (P<0.05) increased by 53% compared to the OVX controls.    
Conclusion: Estradiol supplementation in ovariectomized females is followed by 
stimulatory histological and secretory changes of the mammotrophs. These results 
could serve as indicators of possible prolactinome development upon estradiol ap-
plication in premature menopausal subjects.         
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Introduction
Pituitary mammotrophs, i.e. prolactin- 
(PRL) producing cells, in rats are distributed 
throughout the anterior-ventral part as well as 
in the areas near the gland pars intermedia (1). 
Classification of mammotrophs takes secretory 
granule size as a key criterion and accordingly 
three types of these cells are identified (1, 
2). PRL is a pulsatile secreted polypeptide 
hormone, functionally entwined with ovulation, 
pregnancy or nursing and characterized by a 
significant, age-related rise in females (1, 3, 4). 
Also, the number of female mammotrophs and 
their DNA content increase with ageing (5, 6). 
Generally, the intensified PRL release with age 
is partly due to dysfunction of the dopaminergic 
mechanism in the hypothalamus (7). Studies in 
postmenopausal subjects have confirmed these 
secretory changes as far-reaching, since PRL 
levels do not decrease in that period of life (8).
Premature menopause, linked with estrogen 
deficiency and infertility in young women, 
can develop spontaneously or may be caused 
by iatrogenic factors (9). A whole range of 
profound symptoms such as hot flashes, bone 
deterioration, decreased libido, cardiovascular 
issues and depression are included into its 
manifestation (9, 10). When it comes to the 
mammotroph function in premature menopausal 
females, it was found long ago that PRL levels 
remain within normal range, while the pulsatility 
of secretion flattens (11). Estrogen replacement 
therapy is a common therapeutic approach to 
treat menopausal symptoms, with confirmed 
effectiveness in osteoporosis treatment (12), 
but due to possible adverse effects (breast or 
endometrial cancer, thromboembolic events) 
careful selection of dosage and duration of use 
are advised (13-15).
Literature data have already pointed out that 
estradiol potently influences mammotroph 
differentiation, function and proliferation in 
vitro (16), while its effects in prematurely 
menopausal females remain insufficiently 
elaborated. Since estradiol application in 
menopausal subjects may change the histological 
parameters of pituitary mammotrophs and 
PRL secretion, our aim was to explain the 
phenomenology of potential estradiol-caused 
changes in ovariectomized adult female rats 
using modern histological and biochemical 
methodologies. Thus, in our model reflecting 
premature natural/iatrogenic menopause, we 
investigated the immunohistomorphometric 
characteristics of pituitary mammotrophs, using 
a design-based stereological approach, as well 
as their secretory ability, by measuring the 
optical density (OD) of immunostaining and the 
circulating PRL levels (17, 18).
Materials and Methods
Experimental design
In this experimental study, 21 female Wistar 
rats 12-weeks old (with the average body mass 
about 290 g) were housed in the experimental 
animal unit of the Institute for Biological 
Research "Siniša Stanković" and maintained 
under standard laboratory conditions (room 
temperature at 22 ± 2˚C and a 12 hour light: 
12 hour dark cycle). Food and water were 
available ad libitum. The rats were divided into 
three groups (n=7). Females from two groups 
were bilaterally ovariectomized (OVX) under 
nembutal anesthesia (25 mg/ml distilled water). 
One month after ovariectomy, the first OVX 
group was treated through an intraperitoneal 
(i.p.) injection with 0.625 mg/kg b.m. of 
estradiol dipropionate (Oestradiol, Galenika 
a.d., Beograd, Srbija, OVX+E) per day for 4 
weeks. The estradiol dose was selected based 
upon a previous work reporting its usage 
in clinical practice to treat postmenopausal 
women (19). Female rats in the second group 
represented long-term OVX controls injected 
with sterile olive oil for 4 weeks. The third 
group consisted of non-ovariectomized females 
injected with sterile olive oil (C) for 4 weeks. All 
females were sacrificed under ether anesthesia 
(ether ad narcosis Ph. Iug. III., Lek, Ljubljana, 
Slovenia) 24 hours after the last treatment.
All animal procedures were adjusted to the 
European Communities Council Directive 
(86/609/EEC) and were approved by the Ethical 
Committee for the Use of Laboratory Animals 
of the Institute for Biological Research "Siniša 
Stanković", University of Belgrade, Serbia 
(Approval No. 2-12/13).
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Light microscopy and immunocytochemistry
After decapitation, pituitary glands were 
excised, weighed and fixed in Bouin’s solution 
for 48 hours at room temperature. After 
dehydration in a series of increasing ethanol 
gradient, the pituitaries were enlightened in 
xylene and embedded in paraplast. Series 
of seven sections (5 mm) of the pituitary cut 
through three tissue levels (dorsal, middle 
and ventral portion) of the pars distalis were 
used for immunostaining. Mammotrophs were 
identified by immunohistochemistry using the 
peroxidase-antiperoxidase (PAP) method as 
previously described in detail (4).
Morphometry
Image acquisition, morphometric assessment 
and digital imaging were performed using 
a light microscope (Olympus BX-51, 
Olympus, Japan) equipped with a microcator 
(Heidenhain MT1201, Heidenhain, USA) to 
control movements in the z-direction (0.2 
µm accuracy), a motorized stage (Prior, Prior 
Scientifi Inc., USA) for stepwise displacement 
in the x-y direction (1 µm accuracy), and a CCD 
video camera (PixeLink, PixeLINK, Canada) 
connected to a 19” LCD computer monitor 
(Dell 1907FPc, Dell Inc., Round Rock, TX, 
USA). Image acquisition and stage movement 
were controlled by the newCAST stereological 
software package [Visiopharm Integrator 
System (VIS), version 2.12.1.0, Visiopharm, 
Denmark] running on a personal computer.
Volume density (VV) represents the percentage 
of immunoreactive mammotrophs in the 
pituitary glands of experimental and control 
female rats. Two sections from the dorsal, three 
from the middle and two from the ventral part 
of rat pituitary glands were analyzed (the same 
sections were used in the subsequent estimation 
of number of mammotrophs per unit area-mm2 
and cell volume determination). The counting 
area was defined using a mask tool. The new 
CAST software generated an interactive test 
grid, characterized by uniformly spaced test 
points for histomorphometric assessment. Test 
points hitting the immunoreactive mammotrophs 
and the uncolored phase of adenohypophysis 
were determined. VVs of mammotrophs were 
calculated as the ratio of the number of points 
hitting immunoreactive mammotrophs with 
nuclei divided by the number of points hitting 
the uncolored phase of adenohypophysis:
VV (%)=Pp/Pt×100.
Pp=points hitting the immunoreactive 
mammotrophs with nuclei, Pt=points of the 
test system hitting the uncolored phase of 
adenohypophysis.
VV of mammotrophs was calculated for each 
analyzed section. Then, the average value for 
seven analyzed sections was calculated and it 
represents the VV of mammotrophs in a pituitary 
gland per animal.
The number of mammotrophs per mm2 was 
also calculated. In the first step, the areas of 
analyzed sections were determined by the 
Measure Properties option (Polygon area) and 
then, by simple point counting, the number of 
immunoreactive mammotrophs was estimated. 
Additionally, the number of mammotrophs was 
expressed per unit area (mm2). The single cell 
volume (μm3) of mammotrophs was measured 
using the rotator tool.
Pituitary mammotrophs optical density 
measurements
The Windows based ImageJ program (Image J, 
version 1.50f) was used for the analysis. Namely, 
30 unbiasedly captured images (the microscopic 
tool has already been described: 2088×1550 
pixels, ×63 objective magnification) per 
mammotroph specific-immunostained pituitary 
per animal were analyzed. Initially, the spectral 
deconvolution method of 3,3′-diaminobenzidine 
tetrahydrochloride (DAB)/Hematoxylin color 
spectra was performed, using optimized OD 
vectors of the color deconvolution plug-in for 
adequate separation of the DAB color spectra. 
To determine the OD for the red, green and blue 
(RGB) channel of Hematoxylin and DAB, we 
followed the protocol as previously described 
by Ruifrok and Johnston (20) and Varghese et 
al. (21). Since the OD is proportional to the 
concentration of the stain in mammotrophs, the 
amount of stain present is a factor determining 
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the OD at a wave length specific to the stain, 
according to the formula:
OD=-log10 (IC/I0.C),
where I represents the transmitted light, IC 
is the intensity of detected light after passing 
through a specimen and I0.C refers to the intensity 
of light entering the specimen.
Hormonal analysis
Blood was collected from the trunk and 
separated sera samples of all animals were 
stored at the same time at -70˚C until assayed. 
Serum concentrations of PRL in control and 
experimental female rats were measured by the 
non-isotopic two-step assay (Delfia) method 
(hPRL-Delfia kits, LKB, Turku, Finland).
Statistical analysis
Morphometric and hormonal data obtained 
for each group of female rats were averaged 
and SD was calculated with STATISTICA® 
version 7.0 (StatSoft Inc., USA). One-way 
analysis of variance (ANOVA), followed by the 
multiple range test of Tukay (honest significant 
difference) HSD was used for comparison of 
the differences between groups. A probability 
value of 5% or less was considered statistically 
significant.
Results
The values of body mass, and absolute and 
relative pituitary weights are shown in Table 1. 
OVX caused significant (P<0.05) increase in 
the body mass of adult female rats by 16% in 
comparison with non-ovariectomized females, 
while absolute and relative pituitary weights 
were not significantly changed. In OVX+E 
females, body mass was significantly (P<0.05) 
decreased by 32% in comparison with the OVX 
group. Absolute and relative pituitary weights 
in the OVX+E group were 2.6-fold (P<0.05) 
and 3.4-fold (P<0.05) higher than in the OVX 
group, respectively.
In control, pituitary glands’ mammotrophs 
were spread throughout the pars distalis. These 
cells were oval or polygonal in shape and strong 
immunoreactivity was pronounced in their 
cytoplasm. After ovariectomy, mammotrophs 
were irregularly shaped and decreased 
intensity of immunostaining was noticed. 
In OVX+E females, the mammotrophs were 
irregularly shaped, with dark colored secretory 
granules (Fig.1). The quantitative analysis of 
mammotrophs showed that ovariectomy caused 
significant (P<0.05) decrease of their OD, VV and 
number per mm2 by 29, 27 and 34%, respectively, 
in comparison with control non-ovariectomized 
females. In the OVX+E group, significant 
(P<0.05) increases in OD, cell volume, VV 
and number of mammotrophs per mm2 by 181, 
15%, 5.8-fold and 5.2-fold, respectively, were 
observed when compared to OVX animals 
(Figs.2, 3). The serum concentration of PRL 
in OVX females was significantly (P<0.05) 
decreased by 14% in comparison with non-
ovariectomized controls. In OVX females, 
estradiol treatment significantly (P<0.05) 
increased PRL concentration in serum by 53% 
compared to the OVX control (Fig.3).
Table 1: The body mass and absolute and relative pituitary weights among C, OVX and OVX+E adult female rats
Group Body mass (g) Absolute pituitary weight (mg) Relative pituitary weight (mg%)
C 288 ± 18 14.2 ± 1.4 5.0 ± 0.7
OVX 334 ± 40a 16.5 ± 3.4 5.6 ± 1.3
OVX+E 227 ± 39b 42.8 ± 6.5b 18.8 ± 5.3b
Results are given as means ± SD (n=7). 
C; Non-ovariectomized, OVX; Ovariectomized, OVX+E; Estradiol-treated ovariectomized, a; P<0.05 vs. C , b; P<0.05 vs. OVX.
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Fig.1: Immunopositive mammotrophs in pars distalis of the 
pituitary gland from C, OVX and OVX+E adult female rats 
(magnification: ×63, bar=16 µm).
C; Non-ovariectomized, OVX; Ovariectomized, and OVX+E; 
Estradiol-treated ovariectomized.
Fig.2. Morphometric parameters of pituitary mammotrophs. A. 
Vv (%), B. Number per mm
2, and C. Volume (µm3) in C, OVX and 
OVX+E adult female rats, results are given as means ± SD (n=7).
C; Non-ovariectomized, OVX; Ovariectomized, OVX+E; Estradiol-
treated ovariectomized, a; P<0.05 vs. C, and b; P<0.05 vs. OVX.
A
B
C
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Fig.3. Secretory ability of pituitary mammotrophs. A. OD of 
pituitary mammotrophs and B. Serum PRL levels (mU/L) in C, 
OVX and OVX+E adult female rats, results are given as means 
± SD (n=7).
OD; Optical density, PRL; Prolactin, C; Non-ovariectomized, OVX; 
Ovariectomized, OVX+E; Estradiol-treated ovariectomized, a; 
P<0.05 vs. C, and b; P<0.05 vs. OVX.
Discussion
Ovariectomized adult female rats, reflecting 
premature natural/iatrogenic menopause (17, 18), 
were used in our experiment to investigate the 
histological parameters and secretory ability of their 
pituitary mammotrophs upon estradiol application. 
In brief, estradiol caused a significant increase in the 
number and size of mammotrophs, and positively 
affected the synthesis and secretion of PRL, based on 
OD and serum PRL levels determination.
Firstly, we have provided evidence that 
hypoestrogenism, caused by ovariectomy, leads 
to an increase in body mass. Kurachi et al. (22) 
observed increased body mass upon ovariectomy 
accompanied by adipocyte hypertrophy. Estrogen 
withdrawal provoked by ovariectomy may 
influence body mass regulation at the central level, 
given the fact that estrogen receptors (ERs) α and 
β are found in the hypothalamic areas responsible 
for body mass regulation. In ERα deficient mice, 
a significant adipose tissue gain is observed, 
indicating a role of estrogen in the central 
regulation of body mass (23). Increases in the 
hypothalamic neuropeptide Y (NPY) expression 
(24) and decreases in hypothalamic corticotrophin-
releasing hormone (CRH) immunoreactivity 
(25), both of which may promote hyperphagia, 
have also been established after ovariectomy. 
These changes in hypothalamic NPY and CRH 
could be explained by central leptin insensitivity 
associated with increased body mass in estrogen-
deficient rats (26). Herein, chronic treatment of 
ovariectomized female rats with estradiol caused 
a significant body mass reduction in comparison to 
ovariectomy alone. Estrogen replacement therapy 
has already been shown to decrease body mass and 
food intake by the suppression of NPY or galanin-
like peptidergic systems in the hypothalamic 
arcuate nucleus or medial preoptic area (27, 28). 
Furthermore, estradiol treatment normalized 
all the changes in energy balance induced by 
ovariectomy, indicating that estrogen deficiency is 
responsible for energy imbalance (26).
The further course of our study implied the 
examination of histological parameters of 
pituitary mammotrophs together with PRL levels 
measurement after ovariectomy and subsequent 
estradiol treatment. Mammotrophs generally 
show morphological, functional and physiological 
heterogeneity, the characteristics which are 
closely associated with estrogenic environment 
(29). Bearing in mind that the mammotroph 
cell population shows a remarkable ability 
to numerically change in response to various 
physiological and experimental conditions (30), 
their decreased VV and number per mm
2 in the 
hypoestrogenic milieu, caused by ovariectomy 
in our experiment, could be explained by the 
transdifferentiation of mammotrophs into 
gonadotropic cells. Transdifferentiation within the 
pituitary hormone-producing cell population is 
suggested to be an important event that aimed at 
providing homeostasis during specific physiological 
challenges (31). In line with the observed decrease 
in mammotroph immunohistomorphometric 
A
B
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parameters and their potential transdifferentiation, 
serum concentrations of PRL expectedly fell 
in our study. Finally, the absolute and relative 
pituitary weights in our experimental set-up 
remain unchanged, which can also be supported 
by the gonadotropic cell population rise after 
transdifferentiation and some partially achieved 
equilibrium in this respect.
Chronic treatment of our ovariectomized 
female rats by estradiol led to an increase in OD 
values, individual cell volume, VV and number 
of mammotrophs per mm2, which was followed 
by increased serum concentrations of PRL. The 
stimulatory effect of estradiol observed could be 
explained by the events at both the hypothalamic 
and the pituitary levels. Namely, at the level of 
hypothalamus, estrogen facilitates the release 
of hypophysiotrophic stimulatory factors (32), 
acting through widely present ERs in numerous 
hypothalamic neuronal populations (33). At the 
pituitary level, estrogen mediates the action of 
locally produced growth factors like insulin growth 
factor-1 (IGF-1), fibroblastic growth factor-2 
(FGF-2) and epidermal growth factor (EGF) 
(34-36). In line with this, the increased values of 
stereological parameters (mammotroph volume 
and VV) observed are in coherence with promoted 
mammotroph cell synthetic activity as well as 
proliferation due to increased local production of 
FGF-2 in an estrogen environment (37). Based 
on the herein observed intensive mammotroph 
immunostaining/high OD, increased cell volume 
and elevated PRL levels, processes of PRL 
synthesis and secretion obviously remain under the 
stimulatory estradiol influence, as already reported 
(16). To note, PRL gene expression is enhanced 
through a mechanism that is mediated directly by 
the anterior pituitary ERs (38). Finally, estrogen 
promotes the mammotroph cell proliferation 
and early development of their hyperplasia by 
inducing Pit-1 transcription factor expression, 
which is considered the strongest predictor of 
prolactinomas (37, 39).
Conclusion
The main contribution of our results to the 
investigation field is reflected in the detected ability 
of mammotrophs to change their appearance, size 
and secretion according to the varying estrogen 
environment, like ovariectomy and ovariectomy 
followed with estradiol treatment. By applying a 
modern histological approach, the mammotroph 
cell volume, VV, number of mammotrophs per mm
2 
and their OD were estimated, providing insight 
into the dynamics of mammotroph cell population 
in this respect. From the biomedical point of view, 
these quantitative and analytical histology based 
information could be relevant as an indicator of 
possible prolactinome or some other PRL-related 
disorder development upon estradiol application 
to premature menopausal subjects.
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